<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Amiodarone: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i118.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i118.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i118.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i116.htm">Anti-arrhythmics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i117.htm" title="Previous: Adenosine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i119.htm" title="Next: Disopyramide">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i118">Amiodarone</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Amiodarone</b>
          has the following interaction information:
        </p><div>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i551.htm">Acetazolamide</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with acetazolamide </td><td></td></tr><tr><td><a href="41001i1012.htm" name="_1012">Agalsidase Alfa and Beta</a></td><td> amiodarone possibly inhibits effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i809.htm" name="_809">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1168.htm" name="_1168">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  amiodarone advised by manufacturer of artemether/lumefantrine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by atazanavir </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i385.htm" name="_385">Benperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with benperidol—manufacturer of benperidol advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with chloroquine and hydroxychloroquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td> amiodarone possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  amiodarone increased by cimetidine </td><td></td></tr><tr><td><a href="41001i483.htm" name="_483">Colchicine</a></td><td class="cBV"><b> amiodarone possibly increases risk of colchicine toxicity</b></td><td></td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> amiodarone inhibits metabolism of coumarins (enhanced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm" name="_1120">Dabigatran Etexilate</a></td><td class="cBV"><b> amiodarone increases plasma concentration of dabigatran etexilate (reduce dose of dabigatran etexilate)</b></td><td></td></tr><tr><td><a href="41001i480.htm" name="_480">Digoxin</a></td><td class="cBV"><b> amiodarone increases plasma concentration of digoxin (halve dose of digoxin)</b></td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with diltiazem </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with loop diuretics </td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with thiazides and related diuretics </td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm" name="_1152">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td> amiodarone increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with <i>parenteral</i> erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1202.htm" name="_1202">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  amiodarone given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i120.htm" name="_120">Flecainide</a></td><td class="cBV"><b> amiodarone increases plasma concentration of flecainide (halve dose of flecainide)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by fosamprenavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  amiodarone increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1050.htm" name="_1050">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i840.htm" name="_840">Levofloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with levofloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b>manufacturer of  amiodarone advises avoid concomitant use with lithium (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm" name="_842">Nelfinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td>plasma concentration of  amiodarone possibly reduced by orlistat </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i223.htm" name="_223">Phenindione</a></td><td class="cBV"><b> amiodarone inhibits metabolism of phenindione (enhanced anticoagulant effect)</b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm" name="_284">Phenytoin</a></td><td class="cBV"><b> amiodarone inhibits metabolism of phenytoin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone increased by ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  amiodarone given with simvastatin </b></td><td></td></tr><tr><td><a href="41001i455.htm" name="_455">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td>possible increased risk of ventricular arrhythmias when  amiodarone given with sulfamethoxazole (as co-trimoxazole)—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td></td></tr><tr><td><a href="41001i371.htm" name="_371">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  amiodarone advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>for concomitant use of  amiodarone and thyroid hormones see <a title="target-block: amiodarone thyroid" href="2416.htm#_2416.2">section 2.3.2</a></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with tolterodine </b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td>possible increased risk of ventricular arrhythmias when  amiodarone given with trimethoprim (as co-trimoxazole)—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with verapamil </b></td><td></td></tr><tr><td><a href="41001i390.htm" name="_390">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p>Amiodarone belongs to <b>Anti-arrhythmics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i116.htm">Anti-arrhythmics</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with other anti-arrhythmics </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  anti-arrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i54.htm">Bupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with bupivacaine </td><td></td></tr><tr><td><a href="41001i906.htm">Levobupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with levobupivacaine </td><td></td></tr><tr><td><a href="41001i873.htm">Prilocaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with prilocaine </td><td></td></tr><tr><td><a href="41001i888.htm">Ropivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with ropivacaine </td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i117.htm">Previous: Adenosine</a> | <a class="top" href="41001i118.htm#">Top</a> | <a accesskey="]" href="41001i119.htm">Next: Disopyramide</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>